Myeloproliferative Neoplasms: Emerging Treatment Options for Myelofibrosis

Presenter: Aaron T. Gerds
Restricted access

Myelofibrosis (MF) is a symptom-forward disease, and its treatment focuses on alleviating those symptoms, as well as improving survival. An initial disease risk assessment is critical for deciding on a course of therapy (and a number of models can be used depending on the available patient information), and anemia can be considered a special case within the treatment algorithms for MF. JAK-STAT inhibition is currently the cornerstone of treatment for MF, but these inhibitors are not perfect. Future research will focus on the microenvironment in reversing fibrosis, immunotherapies, proliferative signaling pathways, epigenetic regulators, and stem cells.

Disclosures: Dr. Gerds has disclosed that he received consulting fees from Celgene Corporation; received grant/research support from Celgene Corporation, CTI BioPharma Corp., Imago Biosciences, Incyte Corporation, and Sierra; and is a scientific advisor for Constellation, Galecto, Kartos, PharmaEssentia, and Promedior, Inc.

Correspondence: Aaron T. Gerds, MD, MS, Cleveland Clinic Taussig Cancer Institute/Case Comprehensive Cancer Center, 9500 Euclid Avenue, CA-60, Cleveland, OH 44195. Email: gerdsa@ccf.org
  • 1.

    Mehta J, Wang H, Usman S, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma 2014;55:595600.

  • 2.

    Cervantes F, Dupriez B, Pereira A, et al. . New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:28952901.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Tefferi A, Guglielmelli P, Larson DR, et al. . Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014;124:25072513.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Rago A, Latagliata R, Montanaro M, et al. . Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. Leuk Res 2015;39:314317.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Tefferi A, Lasho TL, Jimma T, et al. . One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc 2012;87:2533.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Cervantes F, Alvarez-Larran A, Hernandez-Boulda J, et al. . Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004;127:399403.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Cervantes F, Alvarez-Larran A, Hernandez-Boulda J, et al. . Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. Br J Haematol 2006;134:184186.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Cervantes F, Isola IM, Alvarez-Larran A, et al. . Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol 2015;94:17911796.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Chihara D, Masarova L, Newberry KJ, et al. . Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leuk Res 2016;48:15.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Gerds AT, Vannucchi AM, Passamonti F, et al. . A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia [abstract]. Blood 2019;134(Suppl 1):Abstract 557.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Hematology Am Soc Hematol Educ Program 2017;2017:470479.

  • 12.

    Verstovsek S, Mesa RA, Gotlib J, et al. . A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799807.

  • 13.

    Harrison C, Kiladjian J, Al-Ali HK, et al. . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787798.

  • 14.

    Verstovsek S, Gotlib J, Mesa RA, et al. . Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 2017;10:156.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Pardanani A, Harrison C, Cortes JE, et al. . Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 2015;1:643651.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Harrison CN, Schaap N, Vannucchi AM, et al. . Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 2017;4:e317324.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Newberry KJ, Patel K, Masarova L, et al. . Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 2017;130:11251131.

  • 18.

    Palandri F, Breccia M, Bonifacio M, et al. . Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer 2020;126:12431252.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Schieber M, Crispino JD, Stein B, et al. . Myelofibrosis in 2019: moving beyond JAK2 inhibition. Blood Cancer J 2019;99:74.


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 839 839 26
PDF Downloads 252 252 35
EPUB Downloads 0 0 0